TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Brain Stimulation for the Treatment of Adult Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of major depression with a current episode~* Hamilton Rating Scale for Depression score higher than 20~* No response or intolerance to antidepressant medication in the current depressive episode~Exclusion Criteria:~* Current use of antidepressants~* Diagnosis of psychosis or anxiety disorder~* Current substance abuse~* Seizures or history of head trauma

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active prefrontal rTMS phase1 (Type: EXPERIMENTAL): Phase I participants receiving rTMS
- Sham rTMS phase 1 (Type: PLACEBO_COMPARATOR): Phase I participants receiving sham stimulation
- rTMS extension (Type: EXPERIMENTAL): rTMS. Phase II participants, all of whom did not meet remission requirements after phase 1. They all receive active open label rTMS
- Open label antidepressant regimen (Type: EXPERIMENTAL): All patients who met remission who were then transitioned to medications after the TMS trial was completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 2 months (60 to 74 days) inclusive on the day of inclusion~* Born at full term pregnancy (³36 weeks) with a birth weight ≥ 2.5 kg~* Informed consent form signed by the parent(s) or other legal representative~* Able to attend all scheduled visits and to comply with all trial procedures~Exclusion Criteria :~* Participation in another clinical trial in the 4 weeks preceding the trial inclusion~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood-derived products received in the past~* Any vaccination performed or planned in the 4 weeks preceding the first trial visit (except BCG and Hepatitis B, which can not be given within 8 days before the first study visit)~* Vaccination planned in the 4 weeks following any trial vaccination (except BCG and Hepatitis B, which can not be given within 8 days before or after the study vaccine(s) administration)~* History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection (confirmed either clinically, serologically or microbiologically)~* Clinical or serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or HIV infection~* Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases or Haemophilus influenzae type b infection with the trial vaccine or another vaccine~* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of/current seizures~* Febrile illness (axillary temperature ≥ 37.1°C) or acute illness on the day of inclusion

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 74 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): DTacP IPV// PRP\~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
- 2 (Type: EXPERIMENTAL): DTacP-IPV// PRP\~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
- 3 (Type: ACTIVE_COMPARATOR): Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Body Temperature in Persons With Tetraplegia When Exposed to Heat

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Between 18 and 65 years of age;~2. Duration of injury ≥ 1 year;~3. Level of SCI C4-T1;~4. Euhydration (Subjects will be instructed to avoid caffeine and alcohol, maintain normal salt and water intake, and avoid strenuous exercise for 24 hours prior to study); and~5. Age (± 5 years) and gender matched AB control group.~Exclusion Criteria:~1. Known heart and/or blood vessel disease;~2. High blood pressure;~3. Kidney disease;~4. Diabetes mellitus;~5. Acute illness or infection;~6. Dehydration;~7. Pregnant women;~8. Untreated thyroid disease, and~9. Broken, inflamed, or otherwise fragile skin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Tetraplegia (Type: None): Persons with spinal cord injury, level of injury C4-T1, American Spinal Injury Association (ASIA) impairment levels A-B and duration of injury greater than 1 year. Ages 18-65 years old.
- Control (Type: None): Age and gender-matched able-bodied controls. Ages 18-65 years old.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. meet DSM-IV diagnostic criteria for ADHD-combined type;~2. estimated IQ of 75 or higher;~3. agree to comply with the randomly assigned treatment condition;~4. enrolled in full time school at first grade level or higher; AND~5. have a primary teacher available to complete ratings for the entire study duration.~Exclusion Criteria:~1. current or past history of seizures (not including benign febrile seizures) or other neurological disorders;~2. physical conditions that preclude administration of Strattera or other medical illness that might confound study results or increase the safety risk to subjects exposed to study treatments (i.e. marked cardiac conduction delay, etc.);~3. prior failed trial of Strattera defined as 3 weeks or more on a daily dose of Strattera of at least .8mg/kg or a documented inability to tolerate at least .8mg/kg/day;~4. serious forms of psychopathology other than ADHD, such autism, bipolar disorder, schizophrenia or any other psychopathology requiring urgent treatment with psychotropic medication; OR~5. children for whom discontinuation of their current psychotropic medication would represent a serious risk to themselves or others.~The presence of Oppositional Defiant Disorder (ODD), Conduct Disorder (CD) or learning disabilities will not result in exclusion from the study as they are commonly occurring comorbidities that have not been found to moderate response to ADHD treatments (Jensen et al., 2001). Enrollment in special education services will also not be an exclusionary criteria as work by this research group has found that such services do not affect response to ADHD treatments (Niemic, Fabiano, Pelham, \& Fuller, 2002).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Combined therapy (Type: EXPERIMENTAL): atomoxetine plus behavior therapy
- Drug therapy (Type: ACTIVE_COMPARATOR): atomoxetine alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pre-pubescent with no childbearing potential~2. Capable of undergoing an eye exam~3. Subject's legally appointed and authorized representative willing to sign and date an informed consent form (ICF) and, where appropriate, the subject willing to sign an assent form prior to any study-related procedures being performed.~4. Parent/legal guardian and subject are willing and able to follow instructions and can be present for the required study visits and Follow-up Phone Call for the duration of the study.~5. Have a healthy, normal cornea.~Exclusion Criteria:~1. Have participated in an investigational study (drug or device) within the past 30 days.~2. Have a known contraindication to local anesthetics.~3. Children with known autism spectrum disorders or known to have heightened sensitivity.~4. Corneal pathology that would make the corneal sensitivity lower/higher or make the test hard to perform or interpret.~5. Have low visual acuity~6. Manifest nystagmus~7. Have had ocular surgery or general surgery within the past 45 days.~8. Have had an intravitreal injection in either eye within 14 days of randomization.~9. Have ocular surface disease.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- AG-920 (Type: EXPERIMENTAL): Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
- Proparacaine (Type: ACTIVE_COMPARATOR): 0.5% Proparacaine Hydrochloride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for All Participants:~* HIV infected~* HBV infected~* Serum HBV DNA of 100,000 copies/ml or greater~* Positive for serum hepatitis B surface antigen (HBsAg) within 12 weeks prior to study entry~* Agree to use acceptable methods of contraception~* Serum alpha-fetoprotein (AFP) of 50 ng/ml or less within 30 days of study entry. If AFP is greater than 50 ng/ml, the patient must have an imaging study of the liver showing no tumor within 30 days prior to study entry~Inclusion Criteria for Population A:~* Uninterrupted stable HAART regimen at study entry for at least 12 continuous weeks prior to study entry~* HIV viral load of 10,000 copies/ml or less within 12 weeks of study entry~Inclusion Criteria for Population A, Group I:~* Compensated liver disease~* Child-Pugh-Turcotte (CPT) score of less than 7~Exclusion Criteria for Population A, Group I:~* Excess fluid in the space between the membranes lining the abdomen and abdominal organs (ascites)~* Gastrointestinal (variceal) bleeding~* Brain and nervous system damage as a result of liver disease~* Abnormal blood clotting time~Inclusion Criteria for Population A, Group II:~* Decompensated liver disease~* CPT score of 7-12~Inclusion Criteria for Population B:~* Prior HAART regimen~* Never taken TDF as part of HAART regimen~* Serum HBV DNA of 100,000 copies/ml or greater within 12 weeks of study entry~* HIV viral load of greater than 10,000 copies/ml within 12 weeks of study entry~* CPT score less than 13~Exclusion Criteria~* Serious kidney problems within the last 12 months~* Allergic or sensitive to ADV or TDF~* Active hepatitis C virus (HCV) disease or unknown HCV status within 24 weeks of study entry~* Any medical or mental illness that, in the opinion of the investigator, would interfere with the protocol~* Past or current alcohol or drug abuse that would affect the protocol~* Malignancy that, in the opinion of the investigator, would make the patient unsuitable for the study~* Certain anti-HBV drugs within 90 days of study entry or expected use of these agents during the course of the study~* Drugs that may damage the kidneys within 8 weeks prior to study screening or expected use of these agents during the course of the study~* Systemic corticosteroids within 90 days of study entry~* Current use of drugs containing pivalic acid~* Certain investigational anti-HIV agents~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of prostate.~* Metastatic disease~* Candidates for ADT and docetaxel.~* Started ADT with or without first generation anti androgen, but no longer than 12 weeks before randomization~* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Prior treatment with: LHRH agonist/antagonists; second generation androgen receptor (AR) inhibitors such as enzalutamide, ARN-509, darolutamide (ODM-201), other investigational AR inhibitors; CYP17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as antineoplastic treatment for prostate cancer; chemotherapy or immunotherapy for prostate cancer prior to randomization.~* Treatment with radiotherapy/radiopharmaceuticals within 2 weeks before randomization.~* Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)~* Had a prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed 5 years before randomization and from which the subject has been disease-free~* Gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study treatment.~* Inability to swallow oral medications

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel (Type: EXPERIMENTAL): Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel
- Placebo + standard ADT + Docetaxel (Type: PLACEBO_COMPARATOR): Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bacteriophage Therapy of Difficult-to-treat Infections

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with difficult-to-treat bacterial infections~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 91 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be at least 22 years old~* have cataracts in both eyes~* sign the written informed consent~* be willing and able to comply with examination procedures~* understand, read and write English to complete informed consent and questionnaires~* be available for study follow-up visits~Exclusion Criteria:~* currently participating in any other clinical study or have participated in a clinical study during the last 60 days~* have a certain disease/illness such as poorly-controlled diabetes~* have certain ocular conditions such as uncontrolled glaucoma~* Is taking medication that may affect vision~* Subject is pregnant, plan to become pregnant during the study, or is breastfeeding

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational (Type: EXPERIMENTAL): Bilateral implantation with investigational IOL Model ZFR00V
- Control (Type: ACTIVE_COMPARATOR): Bilateral implantation with control IOL Model ZCB00

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Trigeminal Neuralgia~* Male; or non-pregnant/non-lactating female~* Must be willing to cooperate with and understands study instructions~* Signed informed consent prior to entering study~Exclusion Criteria:~* psychiatric illness~* severe liver or cardiovascular disease~* renal impairment, low white cell count~* malignancy~* pregnancy or lactation~* alcohol or recreational drug abuse~* and positive tests for human immunodeficiency virus or hepatitis B or C.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamictal® (Type: EXPERIMENTAL): Lamictal® was used as the active medication in this study.
- Tegretol® (Type: ACTIVE_COMPARATOR): Tegretol® was employed as the control for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female cigarette smokers, 18- 75 years, motivated to stop smoking and considered suitable for a smoking cessation attempt.~* Smoked an average of at least 10 cigarettes per day during past year and during the month prior to the screening visit, and exhaled carbon monoxide (CO) \>10 ppm at screening.~* For Neuropsychiatric cohort- subjects must have proper diagnosis as outlined in protocol.~Exclusion Criteria:~* Subjects with a past or current diagnosis of one of the following disorders:~  a. Psychotic Disorders:~* Schizophreniform~* Delusional Disorder~* Psychotic Disorder NOS b. All Delirium, Dementia, and Amnestic and Other Cognitive Disorders c. All Substance Induced Disorders (Other than nicotine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
- varenicline (Type: ACTIVE_COMPARATOR): None
- bupropion (Type: ACTIVE_COMPARATOR): None
- Nicotine Replacement Therapy Patch (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete